{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Among the first phase of 12 patients, there is at least 58% probability of observing one or more rare (7% true probability) events, and 83% probability of observing toxicities that have a true occurrence of at least 15%. Among the total cohort of 37 patients, there is at least 85% probability of observing one or more rare (5% true probability) events, and 95% probability of observing toxicities that have a true occurrence of at least 8%. With 37 treated patients, the maximum width of a 90% two-sided exact binomial confidence interval for any estimated adverse event proportion will be no wider than +/- 14%.","groups":[{"description":"Patients receive nivolumab IV over approximately 60 minutes once every 2 weeks for up to 46 doses in the absence of disease progression or unacceptable toxicity.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nNivolumab: Given IV","id":"OG000","title":"Cohort A (Nivolumab - Closed to Accrual on 21-Oct-2015)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Please see the adverse events module for detailed list of adverse events. Percentage of participants who experienced an adverse event.","reportingStatus":"POSTED","timeFrame":"Up to 4 cycles","title":"Incidence of Toxicity, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (Version 5.0 Beginning April 1, 2018) (Cohort A)","type":"SECONDARY","unitOfMeasure":"Participants"}